Reset filter
Mots-clés
Common Data Elements (CDE) ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

414 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

CDASH Concomitant Medication - Concomitant medication

- 20/06/2018 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 2 Langues
Groupes Item: General information, Details
translated and modified from CDASH 2011-10-24 http://www.cdisc.org

CDASH Adverse Event - Adverse Event

- 09/03/2020 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 2 Langues
Groupes Item: General information, Details Adverse Event
translated and modified from CDASH Adverse Event 2011-10-24 http://www.cdisc.org/

CDASH Demographics - Demographics

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 9 Eléments de données, 2 Langues
Groupe Item: Demographics
modified from http://www.cdisc.org

CDASH Substance use

- 20/06/2018 - 1 Formulaire, 3 Groupes Item, 20 Eléments de données, 2 Langues
Groupes Item: Substance use – Cigarettes, Substance use – Cigars, Substance use – Alcohol
modified from http://www.cdisc.org

CDASH Subject Characteristics

- 20/06/2018 - 1 Formulaire, 1 Groupe Item, 5 Eléments de données, 2 Langues
Groupe Item: Subject Characteristics
modified from http://www.cdisc.org

CDASH Subject Characteristics - CDASH LAB (Scenario 2)

- 20/06/2018 - 1 Formulaire, 16 Groupes Item, 95 Eléments de données, 1 Langue
Groupes Item: LAB Information, CBC LAB Results – Leukocytes, CBC LAB Results – Neutrophils, CBC LAB Results – Lymphocytes, CBC LAB Results – Monocytes, CBC LAB Results – Eosinophils, CBC LAB Results – Basophils, CBC LAB Results – Erythrocytes, CBC LAB Results – Hemoglobin, CBC LAB Results – Hematocrit, CBC LAB Results - Platelet Count, CBC LAB Results - Ery. Mean Corpuscular Volume, CBC LAB Results - Mean Platelet Volume, CBC LAB Results - Ery. Mean Corpuscular Hemoglobin, CBC LAB Results - Ery. Mean Corpuscular HB Concentration, CBC LAB Results - Erythrocytes Distribution Width
modified from http://www.cdisc.org

German Center for Diabetes Research (DZD) - Core Data Set - Base set

- 15/07/2024 - 2 Formulaires, 8 Groupes Item, 147 Eléments de données, 2 Langues
Groupes Item: IG.1, IG.2, IG.3, IG.4, IG.5, IG.6, IG.7, Fragebogen
The German Center for Diabetes Research (DZD) has created a core data set for research on diabetes. It is published with permission by the DZD. The complete metadata and SOP are registered at DOI 10.5281/zenodo.7360000 For more information on the work of the DZD see: www.dzd-ev.de/en or contact: studien@dzd-ev.de German Center for Diabetes Research (DZD) Head Office at Helmholtz Zentrum München Ingolstädter Landstr. 1 85764 Neuherberg, Germany The German and English version of the Baecke Questionnaire in this core data set is based on the original paper by Baecke et al (https://doi.org/10.1093/ajcn/36.5.936), redistributed by ten Velde et al. (https://doi.org/10.1371/journal.pone.0256448), and the German translation and modification by Wagner & Singer (2003). The questionnaire was selectively modified by the German Diabetes Center (DDZ). Changes in this version 4 (15.07.2024) compared to version 3 (26.02.2024) include the addition of the parameters defined in the core data set of the German Centers for Health Research (DZG) (ID of MDM entry: 45851), the addition of laterality-specific blindness and an update of the terminology coding. The coding of the DZG parameters is currently under revision and not included in this current version. The coding of those DZG parameters that were already included in the DZD CDS will be provisionally retained.

Optional Set

3 Groupes Item 46 Eléments de données

EUROPEAN PLATFORM ON RARE DISEASE REGISTRATION (EU RD Platform / ERDRI Common Data Set) - SET OF COMMON DATA ELEMENTS FOR RARE DISEASES REGISTRATION

- 05/07/2022 - 1 Formulaire, 8 Groupes Item, 37 Eléments de données, 22 Langues
Groupes Item: Pseudonym, Personal information, Patient status, Care pathway, Disease history, Diagnosis, Research, Disability
EUROPEAN PLATFORM ON RARE DISEASEREGISTRATION(EU RD Platform): https://eu-rd-platform.jrc.ec.europa.eu/set-of-common-data-elements_en Description taken from the above website (17.02.2021): "The "Set of common data elements for Rare Diseases Registration" is the first practical instrument released by the EU RD Platform aiming at increasing interoperability of RD registries. It contains 16 data elements to be registered by each rare disease registry across Europe, which are considered to be essential for further research. They refer to patient's personal data, diagnosis, disease history and care pathway, information for research purposes and about disability. The "Set of common data elements for Rare Diseases Registration" was produced by a Working Group coordinated by the JRC and composed of experts from EU projects which worked on common data sets: EUCERD Joint Action, EPIRARE and RD-Connect." (For this version some implied additional data elements have been added, e.g. date of onset/diagnosis; data elements identified as multiple answer have been split to several boolean data elements. For "Diagnosis"-data elements additionally the actual diagnosis-code variable has been added) EUROPEAN COMMISSION JOINT RESEARCH CENTRE Directorate F –Health, Consumers and Reference Materials UnitF.1 –Health in Society Title in the other languages: български: ЕВРОПЕЙСКА ПЛАТФОРМА ЗА РЕГИСТРАЦИЯ НА РЕДКИТЕ ЗАБОЛЯВАНИЯ (Платформа на ЕС за РЗ): НАБОР ОТ ОБЩИ ИНФОРМАЦИОННИ ЕЛЕМЕНТИ ЗА РЕГИСТРАЦИЯ НА РЕДКИТЕ ЗАБОЛЯВАНИЯ Dansk: EUROPÆISK PLATFORM FOR REGISTRERING AF SJÆLDNE SYGDOMME (EU RD-platformen): FÆLLES DATAELEMENTER FOR REGISTRERING AF SJÆLDNE SYGDOMME Deutsch: EUROPÄISCHE PLATTFORM FÜR DIE REGISTRIERUNG SELTENER KRANKHEITEN (EU-SK-Plattform): (Titel fehlt) ελληνικά: ΕΥΡΩΠΑΪΚΗ ΠΛΑΤΦΟΡΜΑ ΓΙΑ ΤΗΝ ΚΑΤΑΧΩΡΙΣΗ ΣΠΑΝΙΩΝ NΟΣΩΝ (Πλατφόρμα της ΕΕ για τις ΣΝ): ΣΥΝΟΛΟ ΚΟΙΝΩΝ ΣΤΟΙΧΕΙΩΝ ΔΕΔΟΜΕΝΩΝ ΓΙΑ ΤΗΝ ΚΑΤΑΧΩΡΙΣΗ ΣΠΑΝΙΩΝ ΝΟΣΩΝ Español: PLATAFORMA EUROPEA PARA EL REGISTRO DE ENFERMEDADES RARAS: DE ENFERMEDADES RARAS Eesti: HARVIKHAIGUSTE REGISTREERIMISE EUROOPA PLATVORM (EU RD Platform): HARVIKHAIGUSTE REGISTREERIMISE ÜHISTE ANDMEELEMENTIDE KOGUM Suomi: HARVINAISSAIRAUKSIEN REKISTERÖINNIN EUROOPPALAINEN FOORUMI: YHTEISET DATAELEMENTIT HARVINAISSAIRAUKSIEN REKISTERÖINTIÄ VARTEN Français: PLATEFORME EUROPÉENNE POUR LES REGISTRES DE MALADIES RARES: ENSEMBLE D’ÉLÉMENTS DE DONNÉES COMMUNS POUR LES REGISTRES DE MALADIES RARES Hrvatski: EUROPSKA PLATFORMA ZA REGISTRACIJU RIJETKIH BOLESTI: SKUP ZAJEDNIČKIH PODATKOVNIH ELEMENATA ZA REGISTRACIJU RIJETKIH BOLESTI Magyar: A RITKA BETEGSÉGEK NYILVÁNTARTÁSÁNAK EURÓPAI PLATFROMJA: A RITKA BETEGSÉGEK NYILVÁNTARTÁSÁRA VONATKOZÓ KÖZÖS ADATELEMEK EGYÜTTESE Italiano: PIATTAFORMA EUROPEA PER LA REGISTRAZIONE DELLE MALATTIE RARE (Piattaforma EU RD): INSIEME DEGLI ELEMENTIDI DATICOMUNIPER LA REGISTRAZIONE DELLE MALATTIE RARE Lietuvių: EUROPOS RETŲJŲ LIGŲ REGISTRAVIMO PLATFORMA (ES RETŲJŲ LIGŲ PLATFORMA): BENDRI RETŲJŲ LIGŲ REGISTRAVIMO DUOMENŲ ELEMENTAI Latviešu: EIROPAS RETO SLIMĪBU REĢISTRĀCIJAS PLATFORMA: KOPĪGU DATU ELEMENTI RETO SLIMĪBU REĢISTRĀCIJAI Malti: IL-PJATTAFORMA EWROPEA DWAR IR-REĠISTRAZZJONI TAL-MARD RARI: SETT TA’ ELEMENTI TAD-DATAKOMUNI GĦAR-REĠISTRAZZJONI TAL-MARD RARI Nederlands: EUROPEES PLATFORM VOOR DE REGISTRATIE VAN ZELDZAME ZIEKTEN (EU RD Platform): ZELDZAME ZIEKTEN Polski: EUROPEJSKA PLATFORMA NA RZECZ REJESTROWANIA CHORÓB RZADKICH: REJESTROWANIA CHORÓB RZADKICH Português: PLATAFORMA EUROPEIA PARA O REGISTO DE DOENÇAS RARAS(PLATAFORMA UE-DR): CONJUNTO DE ELEMENTOS DE DADOS COMUNS PARA O REGISTO DE DOENÇAS RARAS Română: PLATFORMA EUROPEANĂ DE ÎNREGISTRARE A BOLILOR RARE: SET DE ELEMENTE DE DATE COMUNE PENTRU ÎNREGISTRAREA BOLILOR RARE Slovenčina: EURÓPSKA PLATFORMA O REGISTRÁCII ZRIEDKAVÝCH CHORÔB (PLATFORMA PRE ROZVOJ VIDIEKA V EÚ): ZRIEDKAVÝCH CHORÔB Slovenščina: EVROPSKA PLATFORMA ZA REGISTRACIJO REDKIH BOLEZNI: BOLEZNI Svenska: EUROPEISKA PLATTFORMEN FÖR REGISTRERING AV SÄLLSYNTA SJUKDOMAR: GEMENSAMMA DATAELEMENT FÖR REGISTRERING AV SÄLLSYNTA SJUKDOMAR

Depression - Adult PhenX Toolkit

- 27/09/2021 - 1 Formulaire, 1 Groupe Item, 36 Eléments de données, 2 Langues
Groupe Item: PhenX - depression - adult protocol
This protocol is divided into two parts. Part I consists of the depression section from the Composite International Diagnostic Interview - Short Form (CIDI-SF), developed for the World Health Organization, and is a screening tool for the general population. Part II consists of the Quick Inventory of Depressive Symptoms (QIDS) that captures the severity of depressive symptoms in the last seven days. ODM derived from: https://cde.nlm.nih.gov Primary source: https://www.phenxtoolkit.org/ Recent publication: Hendershot, T., Pan, H., Haines, J., Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M., and Hamilton, C.M. (2015) Using the PhenX toolkit to add standard measures to a study. Curr. Protoc. Hum. Genet. 86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86 German translation of CIDI-SF not validated. German translation of QIDS: http://www.ids-qids.org/translations/german/QIDS-SR_AU1.0_ger-DE.pdf Permission to publish granted by Carol M. Hamilton.

Acute Coronary Syndrome Common Data Elements - Medication

- 27/09/2021 - 10 Formulaires, 23 Groupes Item, 68 Eléments de données, 1 Langue
Groupes Item: Medication, Aspirin, Anticoagulation, Thrombolytics, Clopidogrel, Low molecular weight heparin, Glycoprotein 2b/3a inhibitors, Unfractionated heparin, Beta-Blocker, Statins, ACE Inhibitors, Angiotensin 2 Receptor Antagonists, Warfarin, Prasugrel, Ticagrelor, Bivalirudin, Fondaparinux, Ticlopidine, Dabigatran, Aldosterone Blocking Agent, Rivaroxaban, Dalteparin, Apixaban
Common Data Elements for Acute Coronary Syndrome

Laboratory

2 Groupes Item 36 Eléments de données

Patient history

1 Groupe Item 8 Eléments de données

ACS-Timepoints

1 Groupe Item 16 Eléments de données

Patient data

2 Groupes Item 27 Eléments de données

Procedures

11 Groupes Item 45 Eléments de données

Diagnosis

8 Groupes Item 29 Eléments de données

CDISC SDTM - Observation Class: Findings - Domain: Drug Accountability

- 27/09/2021 - 59 Formulaires, 1 Groupe Item, 25 Eléments de données, 1 Langue
Groupe Item: Drug Accountability
Standard Data Tabulation Model (SDTM) by the Clinical Data Interchange Standards Consortium (CDISC) Based on SDTM v1.7 and the implementation guide SDTMIG v3.3 (for human clinical trials). Quote from https://www.cdisc.org/standards/foundational/sdtmig: "Where the SDTM provides a standard model for organizing and formatting data for human and animal studies, the SDTMIG is intended to guide the organization, structure, and format of standard clinical trial tabulation datasets. It was developed to support data submitted to a regulatory authority, such as the US Food and Drug Administration (FDA), but is not restricted to use in regulated submissions. SDTM is one of the required standards that sponsors must use as specified in the FDA’s Data Standards Catalog (see section II.C) for NDA, ANDA, and certain BLA submissions effective December 2016. For more information, please visit the Guidance on Standardized Data." Domains and Items from other implementation guides (e.g. SDTM-PGx, SDTM-MD) are not included. Please refer to CDISC for information on the implementation of SDTM and associated CDISC standards, do not rely solely on this adaption of CDISC standards. Codelists from the SDTM Terminology included as far as possible in this general version of SDTM (e.g. in the Findings About Domain they are not included, as they depend on the test/result/domain, they are associated with, e.g. COPD Findings About, Cardiovascular Findings About, ...; other test-specific codelists from other domains). Included are the complete codelists referenced in SDTM v1.7 or SDTMIG v3.3, they may need to be constrained depending on the domain or the specific use case. Codelists taken from NCI page https://www.cancer.gov/research/resources/terminology/cdisc in November 2019. CDISC Intellectual Property Policy Version 1.1 (August 15th 2014) Purpose: In its role of leading the development of standards, CDISC must protect those standards to ensure that, to the extent practicable, they remain neutral, open, compensation (royalty)-free, and without encumbering ties to prior intellectual property. This Intellectual Property Policy (“Policy”) is designed to facilitate the activities of CDISC in promotion of such open Standards, to maximize the adoption of such Standards by protecting against the ownership of such Standards by one party and to protect the legitimate intellectual property rights of Contributors.This Policy ensures that CDISC is in accordance with its Bylaws, other Policies and basic Principles.For more information on CDISC, its Bylaws, Strategic Plan, other Policies and basic Principles, please see the CDISC website at www.cdisc.org. Definitions: 2.1“Affiliate” means any entity that directly or indirectly controls, is controlled by, or is under common control with, another entity, so long as such control exists. “Control” means direct or indirect beneficial ownership of or the right to exercise (a) more than fifty percent (50%) of the voting stock or equity in an entity; or (b) more than fifty percent (50%) of the relevant ownership interest or decision-making authority representing the right to make the decisions for the subject entity in the event that there is no voting stock or equity. In the event such control ceases to exist, such Affiliate will be deemed to have withdrawn as a Member, pursuant to the terms set forth in the withdrawal provisions in Section 8. 2.2“CDISC Group” means any CDISC “Working Team,” “Support Team,” “Task Force,” technical working group, or sub-group of a CDISC team or group. 2.3“Contribution” means any material, suggestion, or other submission offered by a Participant in the process of developing a Draft Standard or Final Standard for the purpose of incorporating such submission into a Final Standard, provided that such submission either (a) exists in a tangible form of expression (including in electronic media); or (b) is a verbal statement that is memorialized in written documentation (such as meeting minutes or a draft standard) and is either confirmed or not objected to by such Participant within fifteen (15) calendar days after its receipt of such memorialization. 2.4“Draft Standard” means any CDISC standard or specification developed by a CDISC Group, prior to adoption and publication as a Final Standard. 2.5“Final Standard” means any CDISC standard adopted and published by CDISC as a Final (production version) Standard. 2.6“Licensee’s Product(s)” means only those specific portions of products (software, tools, data formats, other products or combinations thereof), not the product as a whole, that implement and are compliant with the relevant Required Portions of a Final Standard. 2.7 “Member” means all classes of CDISC membership as set forth in CDISC documentation and their Affiliates, including Corporate Benefactors, Corporate Sponsors, Corporate Members and Associate Members. 2.8“Necessary Claims” means those claims in any patent or patent application in any jurisdiction in the world, excluding design patents and design registrations, that would necessarily be infringed by an implementation of those portions of a particular Final Standard within the scope of the CDISC Group charter in effect at the time such Final Standard was developed. A patent claim is “necessarily infringed” only when it is not possible to avoid infringing it because there is no commercially reasonable, non-infringing alternative for implementing the Required Portions of such Final Standard. Notwithstanding the foregoing, Necessary Claims do not include any claims: (i) that may be contained in the same patent as Necessary Claims but are not themselves Necessary Claims; (ii) that cover solely any portions of any product and any combinations thereof that are not required for compliance with the Final Standard; (iii) that cover any enabling technologies that may be necessary to make or use any product or portion thereof that complies with a Final Standard, but are not themselves expressly set forth in the Final Standard (e.g., semiconductor manufacturing technology, compiler technology, object oriented technology, operating system technology, computers, networks, connectivity protocols, or the like); (iv) that cover implementation examples or reference implementations in the text of a Final Standard; or (v) that cover the implementation of other published specifications/standards developed elsewhere and merely referred to in the body of a Final Standard.Since this definition of Necessary Claims focuses solely on Final Standards, not Draft Standards, for purposes of applying the disclosure obligations in Section 5 of this Policy, references to disclosures of Non-Contributed Necessary Claims “covering a Draft Standard” shall be understood to assume that the Draft Standard at issue would ultimately be adopted, without modification, as a Final Standard. 2.9 “Non-Contributed Necessary Claims” means those Necessary Claims that cover not a Participant’s own Contribution but either: (a) the Contribution of another party; or (b) material that is otherwise included in a Final Standard. 2.10 “Participant” means any party that: (1) formally joins a CDISC Group as a listedparticipant; or (2) makes a Contribution to a CDISC Group; or (3) attends one (1) or more meeting(s)/teleconference(s) of a CDISC Group (in person or by telephone) within a one-year period. Participants and other parties must sign (either in writing or electronically) the document attached to this Policy as Attachment A before formally joining, taking part in, or making a Contribution to each particular CDISC Group. Note: A Participant may be an individual acting in its own individual capacity or an organization, and may or may not be a CDISC Member organization or from a CDISC Member organization. If the Participant is an organization, the Participant may be represented in CDISC Groups by a Representative. 2.11“Representative” means an individual who is identified to CDISC as having authority to participate in CDISC or a CDISC Group on behalf of the Participant organization by which s/he is employed. The actions and statements of such individual(s) will be deemed to legally bind such Representative’s Participant organization and its affiliates. 2.12“Required Portion” means a portion of a Final Standard that is required for an implementation to comply with a Final Standard (also known as a “normative” or “mandatory” portion), but not including any elements that are required solely for conformance with any optional (i.e., “non-normative,” “non-mandatory”) portion(s) of a Final Standard; provided, however, that where a Final Standard contains a choice of two or more portions, and implementing any one of the portions is required to comply with the Final Standard (i.e., mutually exclusive required options), each such portion shall be deemed to be a Required Portion. 3 Compensation-free Patent License Commitment Each Participant agrees that, upon request and subject to Sections 5.1 and 8, it will grant, to all parties implementing a Final Standard developed by a CDISC Group in which it was a Participant, a nonexclusive, compensation-free (i.e., no royalty or other fee), nontransferable, non-sublicensable, worldwide, and otherwise reasonable and non-discriminatory license under such Participant’s Necessary Claims covering such Final Standard, solely to make, have made, use, import, offer to sell, sell, lease, and otherwise distribute and dispose of Licensee’s Products that implement such Final Standard; provided, however, that such commitment to license shall not apply to any Necessary Claims for which the Participant does not have the right to license without obligation of payment of royalties or other material consideration by such Participant to an unaffiliated third party. The commitment to license arising under this Section shall be effective as of the date the party was first deemed to be a Participant in the applicable CDISC Group. 4 Copyright Ownership and Licenses 4.1Copyright Ownership in Final Standards. CDISC shall own the copyright in Final Standards developed by CDISC, subject to the underlying copyright rights of the contributing Participants and other copyright owners. Any publication of a Final Standard shall contain an appropriate copyright notice in the name of CDISC. 4.2Copyright License for Contributions. Upon submitting a Contribution, each contributing Participant grants and agrees to grant (i) to each Participant a non-exclusive, worldwide, perpetual, nontransferable, compensation-free license under the Participant’s copyright rights in the Contribution to reproduce, publish, display, perform, distribute, and create derivative works of the Contribution, solely for the purpose of creating and promoting the Draft Standard and Final Standard for which such Contribution was submitted, and (ii) to CDISC a non-exclusive, worldwide, perpetual, irrevocable, compensation-free license to reproduce, publish, display, perform, distribute, and create derivative works of such Contribution (including any Draft Standard, Final Standard, or portion or derivative thereof incorporating the Contribution), and to freely sublicense such rights through multiple tiers, for the purpose of creating and promoting the Draft Standard and Final Standard and for other CDISC activities. Upon the adoption of a Final Standard, CDISC hereby grants and agrees to grant to all Participants and without limiting the generality of the licenses granted herein is also authorized to grant to other parties a nonexclusive, compensation-free, non-transferable, non-sublicensable, worldwide, perpetual, copyright license to reproduce, publish, display, perform, and distribute the Final Standard solely for the purpose of creating and distributing a Licensee’s Product(s) and any accompanying documentation. CDISC may also sublicense such copyright rights to reproduce, publish, display, perform, and distribute the Final Standard to another standard development organization solely for the purpose of adopting the same standard, subject to the relevant CDISC approval procedures, if any, for such further distribution by other organizations as may be established by the CDISC Board of Directors. All reproductions of a Draft Standard or Final Standard shall include all copyright notices, disclaimers, limitations of liability, and other such statements contained in the original. 5 Treatment of Non-Contributed Necessary Claims 5.1Review Period / Licensing Obligations for Non-Contributed Necessary Claims. To ensure that all Participants have the opportunity to review each proposed Draft Standard as a complete document for purposes of identifying Non-Contributed Necessary Claims, CDISC shall, at least thirty (30) calendar days prior to the finalization of the Draft Standard, notify all Participants via e-mail and post the Draft Standard on the CDISC website for open review. During the review period, each Participant in the CDISC Group that developed the Draft Standard under review (as well as others that choose to take part in such review) shall: (a) review the Draft Standard; (b) disclose, pursuant to Section 5.2, any of its Non-Contributed Necessary Claim(s) covering such Draft Standard that the Participant is not willing to license to all implementers of the resulting Final Standard under the compensation-free and otherwise reasonable and non-discriminatory commitment of Section 3; and (c) submit, prior to the end of the review period, a written licensing declaration for any Non-Contributed Necessary Claim disclosed under subclause (b) indicating whether the Participant will commit to license such disclosed claim(s) at least on reasonable and non-discriminatory (“RAND”) terms and conditions (note, Necessary Claims that cover one’s own Contributions must be licensed compensation-free pursuant to Section 3). If a Participant declares its intent under subclause (c) to license the disclosed Non-Contributed Necessary Claim on a RAND basis, it will have a RAND licensing obligation for such disclosed claim to all implementers of the Final Standard. If instead the Participant declares its intent under subclause (c) not to commit to at least RAND licensing for such disclosed claim and withdraws prior to the end of the review period, such Participant will have no licensing obligation for such disclosed claim. If, however, the Participant fails to comply with either of these two options, it will be deemed to have committed to the compensation-free and otherwise reasonable and non-discriminatory licensing obligation of Section 3 (“Default Licensing Obligation”) for such disclosed claim. Any other Non-Contributed Necessary Claims of such Participants that were not disclosed prior to the end of the review period shall also be subject to the Default Licensing Obligation. For the avoidance of doubt, the Default Licensing Obligation (which obligation actually arose under Section 3 and which the Participant failed to avoid by complying with the disclosure/licensing declaration and (if applicable) withdrawal provvisions of this Section) applies to all of a Partticipant’s undisclosed Non-Contributed Necessary Claims coveringg the Final Standard ultimately resulting from the Draft Standard under review, despite the lack of actual and personal knowledge thereof by any individual Representative who participates in such CDISC Group on behalf of such Participant. In the event that a Participant discloses its intention not to make at least a RAND licensing commitment for certain of its Non-Contributed Necessary Claims, the CDISC Group that developed the affected Draft Standard will, in consultation with the CDISC Board of Directors, determine how best to proceed, such as by attempting to develop a revised version of the Draft Standard that works around the potentially blocking patent claims. If, after the review period ends, a Draft Standard is substantially modified, a subsequent review period shall be conducted, under the terms of Section 5.1, before the revised Draft Standard is adopted and published as a Final Standard. 5.2Minimum Contents of Disclosure. With respect to Non-Contributed Necessary Claims in issued patents and published patent applications subject to disclosure under Section 5.1, a Participant must disclose, at a minimum, the identity of the patent rights holder and/or applicant and the patent number or application number. With respect to unpublished patent applications subject to disclosure under Section 5.1, a Participant must disclose, at a minimum, the existence of the application containing the asserted Non-Contributed Necessary Claim(s) and identify the portion(s) of the Draft Standard on which such asserted claim(s) read(s), but need not disclose identifying information (e.g., application number, application contents). Nothing herein precludes broader disclosure of unpublished patent applications on a voluntary basis or pursuant to a non-disclosure agreement. If any disclosed patent or patent application contains Necessary Claims which, if licensed, would require a payment of royalties or other material consideration to an unaffiliated third party, the Participant must also highlight this fact in its disclosure statement. Nothing in this Section or this Policy imposes any duty on any Representative or Participant to perform a patent search or other search of intellectual property portfolios. 6 CDISC Processes; Statement Regarding Patent Disclosures and Other Issues 6.1CDISC Records of Patent Disclosures / Licensing Declarations. The CDISC President shall promptly provide to the CDISC Board of Directors, in writing, the information contained in any patent disclosure. CDISC shall maintain a file, accessible by the public, which includes all patent disclosure statements and licensing declarations received for any Draft Standard or Final Standard. CDISC shall also provide such information to any party, upon request, in order to facilitate such party’s ability to seek and obtain all known patent licenses necessary to implement a Final Standard in a Licensee’s Product. 6.2CDISC Patent Disclaimers. After CDISC’s adoption of the CDISC IP Policy,all published Final Standards shall include the following disclaimers (or their equivalent):“It is possible that implementation of and compliance with this standard may require use of subject matter covered by patent rights. By publication of this standard, no position is taken with respect to the existence or validity of any claim or of any patent rights in connection therewith. CDISC, including the CDISC Board of Directors, shall not be responsible for identifying patent claims for which a license may be required in order to implement this standard or for conducting inquiries into the legal validity or scope of those patents or patent claims that are brought to its attention.”In addition, when CDISC receives from a patent rights holder a written licensing declaration indicating that a license will be required from such patent rights holder by implementers of a Final Standard, then such published Final Standard shall also add the following statement to the end of the above disclaimer:“Certain patent rights holders have filed a statement of willingness to grant a patent license to all implementers of this standard, consistent with the requirements of the CDISC Intellectual Property Policy. CDISC, including the CDISC Board of Directors, makes no representation as to the reasonableness of any terms or conditions of the license agreements offered by such patent rights holders, and all negotiations regarding such terms and conditions must take place between the individual parties outside the context of CDISC. Further information regarding those parties who have claimed patent rights in the standard and expressed their willingness to provide a license may be obtained from the CDISC President. The user should be aware, however, that it is also possible that other patent rights that have not been disclosed to CDISC may be implicated by implementation of or compliance with the standard.” 6.3CDISC Statements Regarding General Disclaimers, Limitation of Liability, and Copyright License to End Users. All published Final Standards shall also include statements of warranty, disclaimer, and limitation of liability statements substantially similar to those in Section 9.4 and Section 9.5, as well as a copyright notice to end users consistent with Section 1. 7 ConfidentialityAll Contributions and information disclosed as a part of CDISC activities shall be deemed non-confidential, and neither CDISC nor any Participant or Representative assumes any confidentiality obligations. 8 Withdrawal/Termination 8.1A Participant may withdraw from CDISC, or from any CDISC Group, at any time by sending a written notice to CDISC. Withdrawal shall be effective upon receipt of such written notice by CDISC. 8.2Effect of Withdrawal/Termination. Notwithstanding the Participant’s withdrawal or termination, and except (as applicable) as provided in Section 5.1 or Section 8.3, a Participant’s agreement to grant a license under Section 3 or Section 5.1 (as applicable) shall remain in full force and effect for: (1) Necessary Claims covering a Contribution made by the withdrawing/terminating Participant that is incorporated into a Final Standard to which such Contribution was offered (even if such Final Standard is adopted after such Participant’s withdrawal/termination); or (2) Non-Contributed Necessary Claims covering a Final Standard as such Final Standard (or the Draft Standard from which it arose) existed on the date of withdrawal/termination (even if such Final Standard is adopted after such Participant’s withdrawal/termination); and (3) Necessary Claims covering a Final Standard adopted by CDISC after the effective date of the Participant’s withdrawal/termination that: (i) are necessary for the later-adopted Final Standard to be backwards compatible with a prior Final Standard; and (ii) are used in a substantially similar manner, extent, and result as such Necessary Claims were used in such prior Final Standard for which the Participant is obligated to grant licenses. All rights and obligations of the withdrawn/terminated Participant other than those specifically referenced in this Section 8.2 or Section 3, 5.1, or 4.2 shall cease upon such withdrawal/termination. 9 General 9.1 No Other Licenses. Except for the rights expressly provided under this Policy, neither CDISC nor any Participant grants or receives, by implication, estoppel, or otherwise, any rights under any patents, copyrights, or other intellectual property rights. 9.2 No Software Code in Required Portions of Standards. Except for data interchange formats, no Draft Standard or Final Standard, and no Contribution, may include software code (i.e., source code or object code), except for code that will be used for illustrative purposes only and will not be deemed to be a Required Portion of a Draft Standard or Final Standard. 9.3 Representations and Warranties. Each Participant shall be deemed to represent, warrant, and covenant, at the time of a Contribution by such Participant (or by its Representative), that to the best of its knowledge and ability: (a) it holds or has the right to grant all relevant licenses to any of its Contributions in all jurisdictions or territories in which it holds relevant intellectual property rights; (b) there are no limits to the Participant’s ability to make the grants, acknowledgments, and agreements herein; and (c) the Contribution does not subject any Contribution, Draft Standard, Final Standard, or implementations thereof, in whole or in part, to licensing obligations with additional restrictions or requirements inconsistent with those set forth in this Policy, or that would require any such Contribution, Final Standard, or implementation, in whole or in part, to be either: (i) disclosed or distributed in source code form; (ii) licensed for the purpose of making derivative works (other than as set forth in Section 4.2); or (iii) distributed at no charge, except as set forth in Sections 3, 5.1, and 4.2. If a Participant has knowledge that a Contribution made by any Participant or any other party may subject any Contribution, Draft Standard, Final Standard, or implementation, in whole or in part, to one or more of the licensing obligations listed in Section 9.3, such Participant shall give prompt notice of the same to the CDISC President who shall promptly notify all Participants. 9.4 No Other Warranties/Disclaimers. ALL PARTICIPANTS ACKNOWLEDGE THAT, EXCEPT AS PROVIDED UNDER SECTION 9.3, ALL DRAFT STANDARDS AND FINAL STANDARDS, AND ALL CONTRIBUTIONS TO FINAL STANDARDS AND DRAFT STANDARDS, ARE PROVIDED “AS IS” WITH NO WARRANTIES WHATSOEVER, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, AND THE PARTICIPANTS, REPRESENTATIVES , THE CDISC PRESIDENT, THE CDISC BOARD OF DIRECTORS, AND CDISC EXPRESSLY DISCLAIM ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR ANY PARTICULAR OR INTENDED PURPOSE, OR ANY OTHER WARRANTY OTHERWISE ARISING OUT OF ANY PROPOSAL, FINAL STANDARDS OR DRAFT STANDARDS, OR CONTRIBUTION. 9.5 Limitation of Liability . IN NO EVENT WILL CDISC OR ANY OF ITS CONSTITUENT PARTS (INCLUDING, BUT NOT LIMITED TO, THE CDISC BOARD OF DIRECTORS, THE CDISC PRESIDENT, CDISC STAFF, AND CDISC MEMBERS) BE LIABLE TO ANY OTHER PERSON OR ENTITY FOR ANY LOSS OF PROFITS, LOSS OF USE, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, WHETHER UNDER CONTRACT, TORT, WARRANTY, OR OTHERWISE, ARISING IN ANY WAY OUT OF THIS POLICY OR ANY RELATED AGREEMENT, WHETHER OR NOT SUCH PARTY HAD ADVANCE NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 9.6 Publicity. Each Participant consents to the public disclosure and use of its name for purposes of publicly promoting Final Standards, including the use in statements regarding the compliance of the Participant’s Licensee’s Products with a Final Standard, unless such Participant explicitly indicates in writing to the CDISC President such Participant’s refusal to consent to such public disclosure and use of its name. 9.7 Governing Law / Jurisdiction / Venue. This Policy shall be construed and controlled by the laws of the State of Delaware without giving effect to conflict-of-law principles. The parties agree that all disputes arising in any way out of this Policy will be heard exclusively in, and all parties irrevocably consent to jurisdiction and venue in, the state and Federal courts of the State of Delaware. 9.8 Complete Agreement. This Policy (including all documents referenced herein) sets forth the entire understanding between CDISC and its Members and Participants and Representatives regarding the treatment of patent, copyright, and related issues and supersedes all prior agreements, representations, and understandings related thereto. 10 AuthorizationThis document has been approved and is in effect on this date: Name CDISC Board of Directors Date 11 Change ControlThis Policy is the complete and exclusive statement of the Clinical Data Interchange Standards Consortium, Inc.’s (“CDISC”) Intellectual Property policy, consistent with the CDISC Bylaws. Once this Policy has been approved by the CDISC Board of Directors, it will apply to Members and other parties to the extent they are Participants in one or more CDISC Groups. Any future revisions to this Policy (or any document referenced herein) will become effective only upon approval of such revisions by the CDISC Board and only after: (a) CDISC notifies all Members and Participants in writing (such as by e-mail) of such revisions; (b) a clear and conspicuous link to the revised Policy, with the revisions highlighted, is posted on the home page of the CDISC website (currently http://www.cdisc.org/) for all existing Members/Participants and potential new Members/Participants to see; and (c) Participants are afforded at least thirty (30) calendar days from the date of receiving notice of such revisions to withdraw from CDISC or from particular CDISC Groups; provided, however, that ministerial changes to this Policy, such as proofreading corrections or formatting changes, may be executed by the CDISC Board and, upon CDISC Board approval, shall be immediately effective as to all existing and new Participants, so long as a revised version of the Policy containing such ministerial changes is posted on the home page of the CDISC website. Any Participant that withdraws from CDISC or from a CDISC Group prior to the end of this thirty (30)-day period will be subject to the version of the Policy that was in effect prior to the Board-approved revisions, in accordance with its terms and the withdrawal provisions of such version, but will not be subject to new or revised terms of the revised Policy. Any existing Participant that does not so withdraw prior to the end of this thirty (30)-day period will be deemed to have ratified and accepted the revised Policy in its entirety even without written agreement to such revised Policy by such Participant.

Observation Class: Events - Domain: Healthcare Encounters

1 Groupe Item 28 Eléments de données

Observation Class: Events - Domain: Protocol Deviations

1 Groupe Item 16 Eléments de données

Observation Class: Events - Domain: Medical History

1 Groupe Item 27 Eléments de données

Observation Class: Findings - Domain: ECG Test Results

1 Groupe Item 43 Eléments de données

Observation Class: Findings - Domain: Death Details

1 Groupe Item 12 Eléments de données

Observation Class: Events - Domain: Clinical Events

1 Groupe Item 31 Eléments de données

Acute Myeloid Leukemia - Treatment Details

- 20/09/2021 - 13 Formulaires, 6 Groupes Item, 39 Eléments de données, 1 Langue
Groupes Item: Therapeutic procedure; Details, Adverse Event, Hemopoietic stem cell transplant, Platelet Engraftment, Neutrophil Engraftment, Therapeutic procedure; Status
Acute Myeloid Leukemia Common Data Elements Holz

Medical History

6 Groupes Item 20 Eléments de données

Lab: Cytology/Cytogenetics/Cytochemistry

3 Groupes Item 43 Eléments de données

Lab: Molecular Genetics, Immunophenotyping, Cytogenetics

1 Groupe Item 1 Élément de données

Physical Examination/Follow-up

4 Groupes Item 27 Eléments de données

Lab: Infectiology

1 Groupe Item 11 Eléments de données

Lab: Molecular Genetics

1 Groupe Item 23 Eléments de données

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial